229 related articles for article (PubMed ID: 35395766)
21. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
Denmeade SR; Wang H; Agarwal N; Smith DC; Schweizer MT; Stein MN; Assikis V; Twardowski PW; Flaig TW; Szmulewitz RZ; Holzbeierlein JM; Hauke RJ; Sonpavde G; Garcia JA; Hussain A; Sartor O; Mao S; Cao H; Fu W; Wang T; Abdallah R; Lim SJ; Bolejack V; Paller CJ; Carducci MA; Markowski MC; Eisenberger MA; Antonarakis ES
J Clin Oncol; 2021 Apr; 39(12):1371-1382. PubMed ID: 33617303
[TBL] [Abstract][Full Text] [Related]
22. Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer.
Conteduca V; Crabb SJ; Scarpi E; Hanna C; Maines F; Joyce H; Fabbri P; Derosa L; Massari F; Lolli C; Zarif S; Jones RJ; Caffo O; Elliott T; De Giorgi U
Mol Diagn Ther; 2016 Jun; 20(3):255-63. PubMed ID: 27020582
[TBL] [Abstract][Full Text] [Related]
23. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
Bryce AH; Alumkal JJ; Armstrong A; Higano CS; Iversen P; Sternberg CN; Rathkopf D; Loriot Y; de Bono J; Tombal B; Abhyankar S; Lin P; Krivoshik A; Phung D; Beer TM
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):221-227. PubMed ID: 28117385
[TBL] [Abstract][Full Text] [Related]
24. Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received
Bülbül O; Ünek İT; Kefi A; Tuna EB; Bekiş R
Hell J Nucl Med; 2020; 23(3):229-239. PubMed ID: 33306752
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J
Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973
[TBL] [Abstract][Full Text] [Related]
26. Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.
Conteduca V; Crabb SJ; Jones RJ; Caffo O; Elliott T; Scarpi E; Fabbri P; Derosa L; Massari F; Numico G; Zarif S; Hanna C; Maines F; Joyce H; Lolli C; De Giorgi U
PLoS One; 2016; 11(7):e0158952. PubMed ID: 27434372
[TBL] [Abstract][Full Text] [Related]
27. Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer.
Kato H; Furuya Y; Miyazawa Y; Miyao T; Syuto T; Nomura M; Sekine Y; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Anticancer Res; 2016 Nov; 36(11):6141-6149. PubMed ID: 27793943
[TBL] [Abstract][Full Text] [Related]
28. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Hussain M; Fizazi K; Saad F; Rathenborg P; Shore N; Ferreira U; Ivashchenko P; Demirhan E; Modelska K; Phung D; Krivoshik A; Sternberg CN
N Engl J Med; 2018 Jun; 378(26):2465-2474. PubMed ID: 29949494
[TBL] [Abstract][Full Text] [Related]
29. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
[TBL] [Abstract][Full Text] [Related]
30. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.
Salvi S; Casadio V; Conteduca V; Lolli C; Gurioli G; Martignano F; Schepisi G; Testoni S; Scarpi E; Amadori D; Calistri D; Attard G; De Giorgi U
Oncotarget; 2016 Jun; 7(25):37839-37845. PubMed ID: 27191887
[TBL] [Abstract][Full Text] [Related]
31. An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
Miyazawa Y; Sekine Y; Shimizu N; Takezawa Y; Nakamura T; Miyao T; Nakayama H; Kurihara S; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2019 Sep; 79(12):1462-1470. PubMed ID: 31334872
[TBL] [Abstract][Full Text] [Related]
32. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.
De Giorgi U; Hussain M; Shore N; Fizazi K; Tombal B; Penson D; Saad F; Efstathiou E; Madziarska K; Steinberg J; Sugg J; Lin X; Shen Q; Sternberg CN
Eur J Cancer; 2021 Dec; 159():237-246. PubMed ID: 34784577
[TBL] [Abstract][Full Text] [Related]
33. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
Sonpavde G; Pond GR; Berry WR; de Wit R; Armstrong AJ; Eisenberger MA; Tannock IF
Urol Oncol; 2012 Sep; 30(5):607-13. PubMed ID: 20888271
[TBL] [Abstract][Full Text] [Related]
34. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
[TBL] [Abstract][Full Text] [Related]
35. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
[TBL] [Abstract][Full Text] [Related]
36. The value of tumor markers in men with metastatic prostate cancer undergoing [
Yordanova A; Linden P; Hauser S; Feldmann G; Brossart P; Fimmers R; Essler M; Holdenrieder S; Ahmadzadehfar H
Prostate; 2020 Jan; 80(1):17-27. PubMed ID: 31579967
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
38. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Sartor O; Coleman RE; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Vogelzang NJ; Bruland Ø; Kobina S; Wilhelm S; Xu L; Shan M; Kattan MW; Parker C
Ann Oncol; 2017 May; 28(5):1090-1097. PubMed ID: 28453701
[TBL] [Abstract][Full Text] [Related]
39. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract][Full Text] [Related]
40. The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.
Oka T; Hatano K; Okuda Y; Yamamoto A; Uemura T; Yamamichi G; Tomiyama E; Ishizuya Y; Yamamoto Y; Kato T; Kawashima A; Fujita K; Nonomura N
Int J Clin Oncol; 2023 Mar; 28(3):427-435. PubMed ID: 36580184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]